Market Research Logo

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H1 2015


Attention: There is an updated edition available for this report.

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H1 2015’, provides an overview of the Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Overview
Therapeutics Development
Pipeline Products for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Overview
Pipeline Products for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Comparative Analysis
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics under Development by Companies
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Products under Development by Companies
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Companies Involved in Therapeutics Development
Alkeus Pharmaceuticals, Inc.
Biovista Inc.
GenSight Biologics
Santhera Pharmaceuticals Holding AG
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BVA-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BVA-203 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Lebers Hereditary Optic Neuropathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
idebenone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Recent Pipeline Updates
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Dormant Projects
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Product Development Milestones
Featured News & Press Releases
Jun 05, 2014: European Medicines Agency Validates Santhera’s Marketing Authorization Application for Raxone in Leber’s Hereditary Optic Neuropathy
May 07, 2014: Santhera Files Marketing Authorization Application in European Union for Raxone in the Treatment of LHON
Mar 04, 2014: Santhera Presents New Efficacy Data from an Expanded Access Program with Raxone for the Treatment of Leber's Hereditary Optic Neuropathy
Jan 21, 2014: Temporary Authorization for Use Granted for Santhera's Raxone for the Treatment of Leber's Hereditary Optic Neuropathy in France
Mar 22, 2013: Santhera Pharma Withdraws Marketing Authorization Application For Raxone In LHON
Jan 18, 2013: Santhera Pharma Receives Negative Opinion From EMA's CHMP On Marketing Authorization Application For Raxone
Nov 16, 2012: Santhera Pharma Expects CHMP Opinion On MAA For Raxone In Early 2013
Jul 26, 2011: Catena Improves Sight For Patients With Inherited Blindness, Newcastle University Study Finds
Jul 22, 2011: EMA Accepts Santhera's Marketing Authorization Application Of Idebenone For Review In LHON
Jun 06, 2011: Santhera Pharma Presents Nonclinical Data In LHON At Joint Congress Of SOE/AAO 2011
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), H1 2015
Number of Products under Development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Alkeus Pharmaceuticals, Inc., H1 2015
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Biovista Inc., H1 2015
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by GenSight Biologics, H1 2015
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Therapeutics - Recent Pipeline Updates, H1 2015
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Dormant Projects, H1 2015
List of Figures
Number of Products under Development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), H1 2015
Number of Products under Development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report